Cristina Tarango, MD
- Medical Director, Hemophilia Treatment Center
- Professor, UC Department of Pediatrics
- cristina.tarango@cchmc.org
- Board Certified
About
Biography
As a pediatric hematologist, I treat children with conditions such as hemophilia, von Willebrand disease, thrombosis (blood clots) and other blood conditions. I try to treat each patient the way I would want my family members to be cared for. It’s very important for patients and families to take an active role in their care and share in the decision-making.
I was influenced in my career choice by a wonderful pediatrician who cared for me when I was growing up. After I became a pediatrician, I chose the field of hematology because it’s so diverse and interesting. At Cincinnati Children’s, I enjoy working with our dedicated group of physicians as well as our excellent nurse care managers, social workers, child life specialists and other professionals who are so committed to supporting children with blood disorders.
In addition to patient care, I conduct research. My studies are focused on gaining a better understanding of thrombosis and its management in children. I am also involved with studies assessing different treatments for hemophilia, as well as evaluating the immune system in patients with hemophilia, both with and without inhibitors. Inhibitors are antibodies that can prevent treatments from working, which makes it more difficult to stop a bleeding episode.
Outside the hospital, I love spending time with my husband and daughter. I also enjoy traveling, reading and volunteering when I can.
MD: Stanford University School of Medicine, Stanford, CA, 2003.
Residency: Yale-New Haven Hospital, New Haven, CT, 2006.
Fellowship: University of Texas Southwestern Medical Center Dallas, Dallas, TX, 2009.
Certification: Pediatrics, 2006; Pediatric Hematology Oncology, 2011.
Interests
Pediatric bleeding disorders and thrombosis; quality improvement; medical education
Interests
Pediatric bleeding disorders and thrombosis; quality improvement; medical education
Research Areas
Additional Languages
SpanishLocations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Efficacy and safety of thrombolysis for pediatric venous thromboembolism: a systematic review and meta-analysis. Blood advances. 2025; 9(21):5512-5527.
Title: Role of primary VTE prophylaxis in pediatric leukemia, lymphoma, and solid tumors: A systematic review and meta-analysis. Blood. 2025; 146(Supplement 1):3139-3139.
Role in of primary VTE prophylaxis in pediatric patients in hospitalized and critically ill settings: A systematic review and meta-analysis. Blood. 2025; 146(Supplement 1):3137-3137.
Clinically relevant bleeding and heavy menstrual bleeding among patients <21 years old with provoked VTE: Findings from the multinational kids-DOTT trial. Blood. 2025; 146(Supplement 1):316-316.
Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial. Journal of Thrombosis and Haemostasis. 2025; 23(11):3481-3491.
Inhibitors and Obesity: The Prevalence and Strength of Association in People With Haemophilia. Haemophilia. 2025; 31(6):1226-1235.
HTRS2025.P1.6 Clinical Outcomes Over 2 Years of Once-Weekly Efanesoctocog Alfa Treatment in Children From North America With Severe Hemophilia A in the Phase 3 XTEND-ed Long-Term Extension Study. Research and Practice in Thrombosis and Haemostasis. 2025; 9:103026.
Recurrent thrombosis and major bleeding in children treated for VTE. Blood advances. 2025; 9(15):3824-3831.
Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US cohort study. Blood Vessels, Thrombosis & Hemostasis. 2025; 2(3):100082.
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients. Blood advances. 2025; 9(10):2587-2636.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey